Mitochondrial dysfunction RAD51, and Ku80 proteolysis promote apoptotic effects of Dinaciclib in Bcl‐xL silenced cells

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Molecular Carcinogenesis

• Publication date

  2018-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/mc.22771PMID 29240261PMCID PMC6854674
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Survivin inhibitor YM155 induces mitochondrial dysfunction, autophagy, DNA damage and apoptosis in Bcl‐xL silenced glioma cell lines

  2017cited by this paper
• Cell cycle proteins as promising targets in cancer therapy

  2017cited by this paper
• Dissociation of gemcitabine chemosensitization by CHK1 inhibition from cell cycle checkpoint abrogation and aberrant mitotic entry

  2016cited by this paper
• Dinaciclib, a Cyclin-Dependent Kinase Inhibitor Promotes Proteasomal Degradation of Mcl-1 and Enhances ABT-737–Mediated Cell Death in Malignant Human Glioma Cell Lines

  2016influential reference
• DNA damage and the balance between survival and death in cancer biology

  2015cited by this paper
• CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma

  2015cited by this paper
• Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma.

  2015cited by this paper
• CDK1 Inhibition Targets the p53-NOXA-MCL1 Axis, Selectively Kills Embryonic Stem Cells, and Prevents Teratoma Formation

  2015cited by this paper
• Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date

  2015cited by this paper
• Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer.

  2014cited by this paper
• Inhibition of Phosphatidylinositol 3-Kinase/AKT Signaling by NVP-BKM120 Promotes ABT-737–Induced Toxicity in a Caspase-Dependent Manner through Mitochondrial Dysfunction and DNA Damage Response in Established and Primary Cultured Glioblastoma Cells

  2014cited by this paper
• Cyclin-dependent kinase inhibitor therapy for hematologic malignancies

  2013cited by this paper
• PD-0332991, a CDK4/6 Inhibitor, Significantly Prolongs Survival in a Genetically Engineered Mouse Model of Brainstem Glioma

  2013cited by this paper
• Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias

  2013cited by this paper
• Decoding and unlocking the BCL-2 dependency of cancer cells

  2013cited by this paper
• PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.

  2013cited by this paper
• Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma

  2013cited by this paper
• Bortezomib‐induced sensitization of malignant human glioma cells to vorinostat‐induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl‐1 cleavage, and DNA damage

  2013cited by this paper
• CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.

  2012cited by this paper
• Recent advances in the molecular understanding of glioblastoma

  2012cited by this paper
• Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening

  2011cited by this paper
• The combination of chemotherapy with HVJ-E containing Rad51 siRNA elicited diverse anti-tumor effects and synergistically suppressed melanoma

  2011cited by this paper
• Identification of Chemosensitivity Nodes for Vinblastine through Small Interfering RNA High-Throughput Screens

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• The Cyclin-Dependent Kinase Inhibitor SCH 727965 (Dinacliclib) Induces the Apoptosis of Osteosarcoma Cells

  2011cited by this paper
• Bcl-xL regulates mitochondrial energetics by stabilizing the inner membrane potential

  2011cited by this paper
• Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer

  2011cited by this paper
• A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers

  2011cited by this paper
• Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.

  2010cited by this paper
• Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours.

  2010cited by this paper
• Necroptosis as an alternative form of programmed cell death.

  2010cited by this paper
• A novel cyclin-dependent kinase inhibitor down-regulates tumor necrosis factor-alpha (TNF-alpha)-induced expression of cell adhesion molecules by inhibition of NF-kappaB activation in human pulmonary epithelial cells.

  2010cited by this paper
• Designing, optimizing, and implementing high-throughput siRNA genomic screening with glioma cells for the discovery of survival genes and novel drug targets.

  2010cited by this paper
• Functional genomic analysis of glioblastoma multiforme through short interfering RNA screening: a paradigm for therapeutic development.

  2010cited by this paper
• Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.

  2009cited by this paper
• Simultaneous analysis of reactive oxygen species and reduced glutathione content in living cells by polychromatic flow cytometry

  2009cited by this paper
• Identification of Survival Genes in Human Glioblastoma Cells by Small Interfering RNA Screening

  2009cited by this paper
• Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies

  2009cited by this paper
• The BCL-2 protein family: opposing activities that mediate cell death

  2008cited by this paper
• An Integrated Genomic Analysis of Human Glioblastoma Multiforme

  2008cited by this paper
• Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium.

  2008cited by this paper
• The effects of the CDK inhibitor seliciclib alone or in combination with cisplatin in human uterine sarcoma cell lines.

  2007cited by this paper
• A phase I pharmacodynamic study of the effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle markers within the buccal mucosa, plucked scalp hairs and peripheral blood mononucleocytes of healthy male volunteers

  2007cited by this paper
• Cyclin-Dependent Kinase Inhibitors Sensitize Tumor Cells to Nutlin-Induced Apoptosis: a Potent Drug Combination

  2007cited by this paper
• A first-in-man phase I tolerability and pharmacokinetic study of the cyclin-dependent kinase-inhibitor AZD5438 in healthy male volunteers

  2007cited by this paper
• Inhibition of Phosphatidylinositol-3-OH Kinase/Akt Signaling Impairs DNA Repair in Glioblastoma Cells following Ionizing Radiation*

  2007cited by this paper
• Mitochondrial membrane permeabilization in cell death.

  2007cited by this paper
• AG490 influences UCN-01-induced cytotoxicity in glioma cells in a p53-dependent fashion, correlating with effects on BAX cleavage and BAD phosphorylation.

  2007cited by this paper
• Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment

  2006cited by this paper
• Rb inactivation leads to E2F1-mediated DNA double-strand break accumulation

  2006cited by this paper
• Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors.

  2005cited by this paper
• Reactive oxygen species in tumor progression.

  2005cited by this paper
• Targeting of Rad51-dependent homologous recombination: implications for the radiation sensitivity of human lung cancer cell lines

  2005cited by this paper
• Cyclin-dependent Kinase Inhibitors Uncouple Cell Cycle Progression from Mitochondrial Apoptotic Functions in DNA-damaged Cancer Cells*

  2005cited by this paper
• Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells

  2004cited by this paper
• Histone H2AX Phosphorylation as a Predictor of Radiosensitivity and Target for Radiotherapy*

  2004cited by this paper
• Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.

  2004cited by this paper
• Genetic Pathways to Glioblastoma

  2004cited by this paper
• Oxidative Stress Induces Nuclear Loss of DNA Repair Proteins Ku70 and Ku80 and Apoptosis in Pancreatic Acinar AR42J Cells*

  2003cited by this paper
• Angiogenesis: Tumorigenesis and the angiogenic switch

  2003cited by this paper
• Expression of phosphorylated histone H2AX as a surrogate of cell killing by drugs that create DNA double-strand breaks.

  2003cited by this paper
• Double-strand breaks and tumorigenesis.

  2001cited by this paper
• Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death

  2001cited by this paper
• The DNA damage response: putting checkpoints in perspective

  2000cited by this paper
• [Mitochondria and apoptosis].

  2000cited by this paper
• Role for Caspase-Mediated Cleavage of Rad51 in Induction of Apoptosis by DNA Damage

  1999cited by this paper
• Superoxide in Apoptosis

  1998cited by this paper
• Mitochondria and apoptosis.

  1998cited by this paper
• Functional Inactivation of the Retinoblastoma Protein Requires Sequential Modification by at Least Two Distinct Cyclin-cdk Complexes

  1998cited by this paper
• Mutagenicity of oxygen free radicals.

  1982cited by this paper

• Exosomal encapsulation of a steviol derivative SD9 to overcome TRAIL resistance as a highly effective therapy against lung cancer

  2025cites this paper
• Cellular signaling in glioblastoma: A molecular and clinical perspective.

  2024cites this paper
• Applications and mechanisms of the cyclin-dependent kinase 4/6 inhibitor, PD-0332991, in solid tumors.

  2022cites this paper
• Sensitization of cervical cancer cells to radiation by the cyclin-dependent kinase inhibitor dinaciclib

  2022influential citation
• Mitochondrial Dysfunction

  2021cites this paper
• Targeting NAD+ Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma Resistance

  2020influential citation
• Reversing tozasertib resistance in glioma through inhibition of pyruvate dehydrogenase kinases

  2020cites this paper
• Recent progress in development of cyclin-dependent kinase 7 inhibitors for cancer therapy

  2020cites this paper
• Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastoma—backbone or add-on in immune-oncology?

  2020cites this paper
• Extracellular Vesicle Delivery of TRAIL Eradicates Resistant Tumor Growth in Combination with CDK Inhibition by Dinaciclib

  2020cites this paper